Phase II study of lenalidomide in patients with metastatic renal cell carcinoma.

Abstract

BACKGROUND Lenalidomide (LEN) is a structural and functional analogue of thalidomide that has demonstrated enhanced immunomodulatory properties and a more favorable toxicity profile. A Phase II, open-label study of LEN in patients with metastatic renal cell carcinoma (RCC) was conducted to determine its safety and clinical activity. METHODS Patients with… (More)

Topics

Cite this paper

@article{Choueiri2006PhaseIS, title={Phase II study of lenalidomide in patients with metastatic renal cell carcinoma.}, author={Toni K Choueiri and Robert Dreicer and Brian I. Rini and Paul Elson and Jorge A. Garc{\'i}a and Snehal Thakkar and Rachid Baz and Tarek M. Mekhail and Holly A Jinks and Ronald M. Bukowski}, journal={Cancer}, year={2006}, volume={107 11}, pages={2609-16} }